MDxHealth SA (MDXH) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

MDxHealth SA (MDXH) Healthcare & Pipeline Overview

MDxHealth S.A. is a precision diagnostics company focused on urologic solutions, offering innovative prostate cancer genomic testing like SelectMDx and ConfirmMDx. These tests aid physicians in identifying clinically relevant prostate cancer while minimizing invasive procedures, positioning MDxHealth within the growing market for personalized medicine.

What Is the Investment Thesis for MDXH?

MDxHealth operates in the growing field of precision diagnostics, with a focus on prostate cancer. The company's key value drivers include the increasing adoption of its SelectMDx and ConfirmMDx tests, driven by their ability to reduce unnecessary biopsies and improve diagnostic accuracy. With a gross margin of 59.7%, there is potential for profitability as revenue scales. Upcoming catalysts include expanded market access and positive clinical data presentations. However, the company's negative profit margin of -31.1% and reliance on reimbursement approvals pose ongoing risks. Investors should monitor revenue growth, reimbursement landscape changes, and competitive pressures.

Based on FMP financials and quantitative analysis

MDXH Key Highlights

Market capitalization of $34.7M, reflecting its position as a smaller player in the diagnostics market.

• Gross margin of 59.7%, indicating a strong ability to control the cost of goods sold.
• Profit margin of -31.1%, highlighting the company's current challenge in achieving profitability.
• Beta of 0.38, suggesting lower volatility compared to the overall market.
• Focus on urologic solutions, specifically prostate cancer diagnostics, allows for specialized market penetration.

Who Are MDXH's Competitors?

MDXH is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are MDXH's Key Strengths?

Proprietary and innovative diagnostic tests.

• Focus on urologic solutions and prostate cancer.
• Established clinical validation and positive clinical data.
• Experienced management team.

What Are MDXH's Weaknesses?

Negative profit margin and reliance on reimbursement approvals.

• Limited product portfolio focused primarily on prostate cancer.
• Smaller market capitalization compared to larger competitors.
• Geographic concentration in the United States and Europe.

What Could Drive MDXH Stock Higher?

MDXH catalyst: Presentation of new clinical data supporting the use of SelectMDx and ConfirmMDx at upcoming medical conferences.

• Expansion of reimbursement coverage for SelectMDx and ConfirmMDx by major insurance companies.
• Increased adoption of SelectMDx and ConfirmMDx by urologists and healthcare providers.
• Potential regulatory approvals for new diagnostic tests in development.

What Are the Key Risks for MDXH?

Listing risk — at $0.676 the shares sit below the $1.00 minimum bid NASDAQ requires for continued listing.

• Financial-distress signal — its Altman Z-Score of -3.79 sits in the distress zone (elevated bankruptcy risk).
• Inconsistent delivery — missed Wall Street EPS estimates in 6 of the last 8 reported quarters.
• Competition from larger and more established diagnostic companies.
• Changes in reimbursement policies and healthcare regulations.
• Technological advancements that could render their tests obsolete.
• Negative profit margin and reliance on reimbursement approvals.
• Dependence on the success of SelectMDx and ConfirmMDx tests.

What Are the Growth Opportunities for MDXH?

• Expansion of SelectMDx and ConfirmMDx adoption in the United States: The US market represents a significant growth opportunity for MDxHealth. By increasing physician awareness and demonstrating the clinical and economic benefits of its tests, MDxHealth can drive adoption and revenue growth. Focused marketing efforts, strategic partnerships with urology practices, and positive clinical data presentations can accelerate market penetration. The prostate cancer diagnostics market in the US is estimated to be worth over $3 billion annually.
• Geographic expansion into new European markets: MDxHealth has an opportunity to expand its presence in European markets beyond its current footprint. Countries with established healthcare systems and a growing awareness of precision medicine represent attractive targets. Securing reimbursement approvals, establishing distribution networks, and conducting local clinical studies are crucial steps for successful market entry.
• Development and commercialization of new diagnostic tests: MDxHealth can leverage its expertise in molecular diagnostics to develop and commercialize new tests for other urologic conditions or cancers. Expanding its product portfolio can diversify its revenue streams and reduce its reliance on prostate cancer diagnostics. Identifying unmet clinical needs, conducting rigorous research and development, and securing regulatory approvals are essential for successful product development. The global cancer diagnostics market is projected to reach $25 billion by 2028.
• Strategic partnerships and collaborations: Collaborating with pharmaceutical companies, research institutions, and other healthcare providers can accelerate MDxHealth's growth. Partnerships can provide access to new technologies, markets, and funding opportunities. Joint development programs, licensing agreements, and co-marketing arrangements can create synergies and enhance MDxHealth's competitive position. Strategic alliances can also help to validate the clinical utility of MDxHealth's tests and drive adoption.
• Increased focus on digital health and data analytics: MDxHealth can leverage digital health technologies and data analytics to improve its diagnostic accuracy and personalize treatment decisions. Developing algorithms to analyze patient data, integrating with electronic health records, and providing decision support tools to physicians can enhance the value of its tests. Investing in data infrastructure, hiring data scientists, and complying with data privacy regulations are important considerations for successful implementation.

What Are MDXH's Competitive Advantages?

• Proprietary technology and intellectual property related to SelectMDx and ConfirmMDx.
• Established clinical validation and positive clinical data supporting the use of their tests.
• Strong relationships with urologists and key opinion leaders in the field.
• Reimbursement coverage from major insurance companies and government healthcare programs.

What Does MDXH Do?

MDxHealth S.A., established in 2003 and headquartered in Herstal, Belgium, is a commercial-stage precision diagnostics company focused on urologic solutions. Originally named OncoMethylome Sciences SA, the company rebranded to MDxHealth SA in October 2010, marking a strategic shift towards its current focus. The company develops and commercializes innovative molecular diagnostic tests for the early detection and personalized treatment of cancer. Its primary offerings include SelectMDx, a non-invasive urine test, and ConfirmMDx, an epigenetic test. SelectMDx helps to identify patients at a higher risk of having clinically significant prostate cancer, reducing the need for unnecessary biopsies. ConfirmMDx is used to assess whether a repeat biopsy is necessary in men with a previous negative biopsy but who remain at risk. These tests are available in the United States, the Netherlands, Belgium, Spain, Poland, Italy, and other European Union countries, as well as internationally. MDxHealth's solutions aim to provide physicians with a clear clinical pathway to accurately diagnose prostate cancer, improving patient outcomes and reducing healthcare costs associated with traditional diagnostic methods.

What Products and Services Does MDXH Offer?

• Develop and commercialize molecular diagnostic tests for urologic cancers.
• Offer SelectMDx, a non-invasive urine test for prostate cancer risk assessment.
• Provide ConfirmMDx, an epigenetic test to assess the need for repeat prostate biopsies.
• Help physicians identify clinically relevant prostate cancer.
• Minimize the use of invasive procedures like biopsies.
• Improve patient outcomes through early and accurate diagnosis.
• Reduce healthcare costs associated with unnecessary biopsies.

How Does MDXH Make Money?

• Generate revenue through the sale of SelectMDx and ConfirmMDx tests.
• Partner with urology practices and hospitals to offer their diagnostic solutions.
• Seek reimbursement from insurance companies and government healthcare programs.
• Expand market access through strategic partnerships and geographic expansion.

What Industry Does MDXH Operate In?

MDxHealth operates within the medical diagnostics and research industry, a segment experiencing growth driven by advancements in genomic testing and personalized medicine. The industry is characterized by intense competition and stringent regulatory requirements. Companies like Exact Sciences (EXAS) and Genomic Health (now part of Exact Sciences) have established significant market presence in cancer diagnostics. MDxHealth differentiates itself through its focus on urologic solutions and non-invasive testing methods. The global molecular diagnostics market is projected to reach $15.5 billion by 2027, presenting substantial growth opportunities for companies with innovative and clinically validated solutions.

Who Are MDXH's Key Customers?

• Urologists and other physicians who treat prostate cancer.
• Hospitals and clinics that offer prostate cancer diagnostic services.
• Patients who are at risk of or suspected of having prostate cancer.
• Insurance companies and government healthcare programs that reimburse for diagnostic tests.

Wall Street analysts project MDxHealth SA revenue of about $111.1M for fiscal 2026, with EPS near $-0.51. The estimate reflects 4 contributing analysts.

Quarterly Financial Performance: MDxHealth SA

Revenue for MDxHealth SA came in at $27.2M during Jun 2026, a 50.2% contraction versus the preceding quarter. The company recorded a net loss of $11.5M, with diluted EPS of $-0.22. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, MDXH averaged $-0.28 in diluted EPS.

MDXH Valuation & Market Position

With a $34.7M market cap, MDxHealth SA sits in the micro-cap segment of the market. Analyst price targets span from $2.00 to $3.00, with a consensus of $2.50. At the current price of $0.68, that implies approximately 270% upside potential. Relative to its peer group, MDXH's quantitative score of 25/100 is below the peer average of 41/100.

Return on equity for MDxHealth SA stands at 403.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -17.7%, showing how much profit it generates from its asset base. Its free cash flow yield is -5.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.08 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -91.8%, the inverse of the P/E and a quick read on earnings relative to price.

MDxHealth SA's Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -3.79 places it in the distress zone, a signal of elevated financial risk.

MDxHealth SA has missed Wall Street's EPS estimate in 6 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 14.0% below estimates on average.

Company Profile

MDxHealth SA operates in the Medical - Diagnostics & Research industry within the Healthcare sector. It is headquartered in Herstal, BE. The company is led by CEO Michael K. McGarrity. MDXH has traded publicly since 2021.

MDXH Financials

MDXH Latest News

MDXH Analyst Consensus

MDXH MoonshotScore

MDxHealth SA Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources